🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. Ranibizumab

    Regeneron UK Limited

    Macular Degeneration

    phase 3 small molecule completed

    2 trials

  2. Ranibizumab

    Hoffmann-La Roche

    Neovascular Age-related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  3. Recombinant Factor VIIa

    United Therapeutics Europe Ltd

    Burns

    phase 3 small molecule completed

    1 trial

  4. Recombinant Human VEGF Receptor-Fc Fusion Protein

    Biotech Pharmaceutical Co.,

    Neovascular Age-related Macular Degeneration

    phase 3 mab completed

    1 trial

  5. Recombinant human tissue kallikrein

    DiaMedica Therapeutics

    Acute Stroke

    phase 3 small molecule active

    1 trial

  6. Reducing Antibiotics treatment duration

    United Therapeutics Europe Ltd

    Ventilator Associated Pneumonia

    phase 3 small molecule completed

    1 trial

  7. Regorafenib

    United Therapeutics Europe Ltd

    Gastro-Oesophageal Cancer

    phase 3 small molecule active

    1 trial

  8. Relacorilant

    CORCEPT THERAPEUTICS INC

    Hypercortisolism

    phase 3 small molecule completed

    1 trial

  9. Relacorilant, 100 mg and 25 mg

    CORCEPT THERAPEUTICS INC

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule terminated

    1 trial

  10. Remodulin (treprostinil sodium) Injection

    United Therapeutics Europe Ltd

    Peripheral Vascular Disease

    phase 3 small molecule terminated

    1 trial

  11. Remodulin® (treprostinil sodium) Injection

    United Therapeutics Europe Ltd

    Critical Limb Ischemia

    phase 3 small molecule terminated

    1 trial

  12. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye Disease

    phase 3 small molecule completed

    4 trials

  13. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Allergic Conjunctivitis

    phase 3 small molecule completed

    4 trials

  14. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye

    phase 3 small molecule completed

    4 trials

  15. Reproxalap Ophthalmic Solution (0.25%) QID

    Aldeyra Therapeutics

    Dry Eye

    phase 3 small molecule completed

    1 trial

  16. Revefenacin

    Theravance Biopharma Ireland Umited

    Chronic Obstructive Pulmonary Disease, COPD

    phase 3 small molecule completed

    2 trials

  17. Revumenib

    United Therapeutics Europe Ltd

    Acute Myeloid Leukemia, Adult

    phase 3 small molecule active

    1 trial

  18. Ridinilazole

    Summit Therapeutics

    Clostridioides Difficile Infection

    phase 3 small molecule completed

    2 trials

  19. Rifampicin

    United Therapeutics Europe Ltd

    Severe Acute Malnutrition

    phase 3 small molecule active

    1 trial

  20. Riluzole

    United Therapeutics Europe Ltd

    Spinal Cord Injury

    phase 3 small molecule terminated

    1 trial

  21. Risankizumab, Risankizumab placebo solution for infusion, ABBV-066 / Risankizumab, ABBV-066, Risankizumab placebo solution for injection in pre-filled syringe, Risankizumab

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  22. Rituximab

    United Therapeutics Europe Ltd

    Follicular Lymphoma

    phase 3 small molecule completed

    1 trial

  23. Rituximab

    United Therapeutics Europe Ltd

    Kidney Transplant Rejection

    phase 3 small molecule terminated

    1 trial

  24. Rivastigmine Transdermal System

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources